A novelliposomal formulation of dithranol for psoriasis: preliminary results.
We have prepared a novel, aqueous gel-based, liposome-entrapped formulation of dithranol. Herein, we report preliminary observations on its efficacy, tolerability, and cosmetic acceptability in treating stable plaque psoriasis. Nineteen plaques of psoriasis in nine adult patients were treated for six weeks in a prospective, open-label trial. In five patients, there was total clearance of lesions, with more than 50% subsidence in a further two patients. Significantly, there were no reports of lesional or perilesional irritation, and only one patient showed faint brown staining of the skin, which was completely and rapidly reversible. These preliminary results indicate that our liposomal dithranol gel has potential advantages over presently available preparations of dithranol; these may translate into enhanced acceptance of this useful drug by patients and physicians.
Agarwal
Ravindra
R
Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Saraswat
Abir
A
Kaur
Inderjeet
I
Katare
Om Prakash
OP
Kumar
Bhushan
B
D000287:Administration, Topical; D000875:Anthralin / Q000008:administration & dosage* / Q000009:adverse effects; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004337:Drug Carriers; D005260:Female; D006801:Humans; D008081:Liposomes; D008297:Male; D011446:Prospective Studies; D011565:Psoriasis / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D004337:Drug Carriers; D008081:Liposomes; D000875:Anthralin